Literature DB >> 12060133

Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.

Brigitte Kircher1, Stefan Stevanovic, Martina Urbanek, Andrea Mitterschiffthaler, Hans-Georg Rammensee, Kurt Grünewald, Günther Gastl, David Nachbaur.   

Abstract

Donor lymphocyte infusions (DLI) can induce a graft-versus-leukaemia (GvL) reaction in patients with relapsed disease. However, the mechanisms involved in remission induction are not completely known. A patient with chemotherapy-refractory relapse 1 year after human leucocyte antigen (HLA)-identical, unrelated stem cell transplantation (SCT) for bcr/abl-positive common acute lymphoblastic leukaemia (ALL) received a DLI from the original donor, and achieved complete cytogenetic and molecular remission concomitantly with extensive graft-versus-host disease (GvHD). Seven CD8+, donor-derived, alloreactive T-cell clones were generated by stimulating post-DLI remission cells with the patient's pretransplant mature dendritic cells. The minor histocompatibility antigen (mHag) recognized by these T-cell clones was identified as HA-1, a mHag associated with acute GvHD after SCT. Our finding provides evidence of HA-1-associated GvL effects after DLI that paralleled the eradication of full-blown, chemotherapy-refractory ALL relapse after allogeneic SCT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12060133     DOI: 10.1046/j.1365-2141.2002.03536.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

3.  A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

Authors:  Marleen M van Loenen; Renate de Boer; Ellis van Liempt; Pauline Meij; Inge Jedema; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

4.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

5.  Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Authors:  Marie Bleakley; Brith E Otterud; Julia L Richardt; Audrey D Mollerup; Michael Hudecek; Tetsuya Nishida; Colette N Chaney; Edus H Warren; Mark F Leppert; Stanley R Riddell
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

6.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 7.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

8.  Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.

Authors:  B Kircher; K Lätzer; G Gastl; D Nachbaur
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

9.  Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.

Authors:  Jutta Auberger; Johannes Clausen; Wolfgang Willenbacher; Martin Erdel; Eberhard Gunsilius; Andreas Petzer; Günther Gastl; David Nachbaur
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

Review 10.  Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy.

Authors:  Caitlin Linscheid; Margaret G Petroff
Journal:  Am J Reprod Immunol       Date:  2013-02-08       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.